AbbVie has announced that it will present new data from its early oncology research at the American Association of Cancer Research (AACR) Annual Meeting, scheduled for April 25-30, 2025. The presentations will include findings from investigational molecules ABBV-969 and ABBV-514, which are being studied in hard-to-treat tumor types.
Dr. Theodora S. Ross, vice president of early oncology research and development at AbbVie, stated: "As we seek to advance innovative therapies for people living with difficult-to-treat cancers, our early-stage oncology research helps lay the scientific foundation for future innovation that may address profound unmet needs that many patients experience."
ABBV-969 is a dual-targeted antibody-drug conjugate designed to target prostate cancer cells expressing STEAP1 and/or PSMA antigens. It is currently in Phase 1 clinical trials for metastatic castration-resistant prostate cancer (mCRPC). Data on this drug will be presented orally at the meeting.
The company will also showcase data on ABBV-514, a CCR8-targeting antibody in Phase 1 trials for non-small cell lung cancer (NSCLC), head and neck cancer, and other solid tumors. This molecule is noted for its potential in driving anti-tumor immunity by depleting regulatory T cells within tumors.
In addition to these drugs, AbbVie will present analyses based on real-world data concerning treatment resistance and biomarker discovery. These studies aim to provide insights into treatment matching for patients and inform options for therapy sequencing and combination treatments.
Further information about AbbVie's clinical trials can be found on ClinicalTrials.gov.